Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with high unmet medical need.
Midatech’s core platform is a pioneering drug conjugate delivery system based on gold nanoparticles (GNPs) combined with existing drugs for targeted release at specific organs, cells or sites of disease.
Using this platform, Midatech has created a pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers, including liver, pancreatic, ovarian and brain (glioblastoma). The GNP platform and the products derived from it are protected by a strong intellectual property base.
Midatech has formed collaborations and partnerships with universities and speciality and major pharmaceutical companies to develop its platform technologies into a broad number of products in order to achieve a range of potential revenue opportunities.
Midatech operates an in-house GNP manufacturing facility in Bilbao, Spain, which is licensed to produce sterile material suitable for human clinical trials and manufacturing of licensed product.
Midatech’s business model has three key components:
- Development and commercialisation of own products, particularly for rare oncology indications
- Development and commercialisation of partner-supported and licensed products, principally in diabetes, and
- Acquisitions of later stage, strategic and complementary opportunities (products or technologies) that accelerate revenue, and are value-accretive
Midatech was founded in 2000 and is headquartered in Oxford, UK.